New brain zapping technique could silence hallucinations in just two days
NCT ID NCT01022489
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether high-frequency magnetic stimulation (rTMS) can reduce auditory hallucinations in people with schizophrenia. Unlike standard low-frequency treatment that takes 15 days, this approach uses 20 Hz stimulation over just 2 days, guided by brain scans for precision. 72 participants will receive either real or sham treatment to see if it safely and effectively lessens the voices they hear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
repetitive transcranial magnetic stimulation (rTMS) device
What this could lead to
If it works, this could offer a faster, more targeted way to reduce auditory hallucinations in people with schizophrenia, potentially shortening treatment from weeks to days.
What could go wrong
This is a mid-stage trial with only 72 participants, so results may not apply to everyone. The treatment is still experimental, and there is a small risk of seizure or headache.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Caen University Hospital
Caen, 14033, France